Akums Drugs and Pharma bags DCGI nod to unveil type 2 diabetes drug Lobeglitazone in India

"This novel product is the result of in-depth research & development and tireless commitment to the production of new drug formulations for the Indian Market. The tablet has been proven to reduce blood sugar levels, improve lipid and liver profiles, and lower haemoglobin A1C (HbA1C) levels. The fact that we're the first CDMO to do this tells a lot about our focus on innovation to offer more effective treatment for the patients," said Mr. Sanjeev Jain, Managing Director of Akums.

In another statement, Mr. Sandeep Jain, Managing Director of Akums noted the importance of innovation. "It's important that we as drug manufacturers continue to innovate to provide more effective solutions to ailments and diseases. With the Lobeglitazone tablets, what we've put together is a unique formulation that tackles type 2 diabetes by addressing the root causes in a more effective way; by affecting the relationship between the PPAR gamma, insulin, and fat cells to improve insulin resistance, among other things," he said.

Lobeglitazone is a film-coated tablet made up of Lobeglitazone Sulfate equivalent to Lobeglitazone at 0.5 mg. It is approved by the Drugs Controller-General of India and offers a number of advantages, including higher safety profile, higher effectiveness in lower dosage, lower risk of hypoglycemia, and improved pancreatic beta-cell function, among others.

It is a safe and well-tolerated formulation that offers repose to diabetic patients.